Dublin, Dec. 17, 2021 (GLOBE NEWSWIRE) -- The "Global Companion Diagnostics Partnering Terms and Agreements 2010-2021" report has been added to ResearchAndMarkets.com's offering.
The Global Companion Diagnostics Partnering Terms and Agreements 2010-2021 report provides comprehensive access to available deals and contract documents for over 500 Companion Diagnostics deals.
The report provides a detailed understanding and analysis of how and why companies enter Companion Diagnostics partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.
This report provides details of the latest Companion Diagnostics agreements announced in the life sciences since 2010.
The report takes the reader through a comprehensive review Companion Diagnostics deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Companion Diagnostics partnering deals.
The report presents financial deal term values for Companion Diagnostics deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.
The middle section of the report explores the leading dealmakers in the Companion Diagnostics partnering field; both the leading deal values and most active Companion Diagnostics dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.
One of the key highlights of the report is that over 500 online deal records of actual Companion Diagnostics deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.
In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
Key benefits
- In-depth understanding of Companion Diagnostics deal trends since 2010
- Access to headline, upfront, milestone and royalty data
- Detailed access to actual Companion Diagnostics contracts entered into by leading biopharma companies
- Identify most active Companion Diagnostics dealmakers since 2010
- Insight into terms included in a Companion Diagnostics partnering agreement, with real world examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Companion Diagnostics Partnering Terms and Agreements includes:
- Trends in Companion Diagnostics dealmaking in the biopharma industry since 2010
- Analysis of Companion Diagnostics deal structure
- Access to headline, upfront, milestone and royalty data
- Access to Companion Diagnostics contract documents
- Leading Companion Diagnostics deals by value since 2010
- Most active Companion Diagnostics dealmakers since 2010
In Global Companion Diagnostics Partnering Terms and Agreements 2010-2021, the available deals are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Specific therapy target
- Technology type
Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in Companion Diagnostics dealmaking
2.1. Introduction
2.2. Companion Diagnostics partnering over the years
2.3. Most active Companion Diagnostics dealmakers
2.4. Companion Diagnostics partnering by deal type
2.5. Companion Diagnostics partnering by therapy area
2.6. Deal terms for Companion Diagnostics partnering
2.6.1 Companion Diagnostics partnering headline values
2.6.2 Companion Diagnostics deal upfront payments
2.6.3 Companion Diagnostics deal milestone payments
2.6.4 Companion Diagnostics royalty rates
Chapter 3 - Leading Companion Diagnostics deals
3.1. Introduction
3.2. Top Companion Diagnostics deals by value
Chapter 4 - Most active Companion Diagnostics dealmakers
4.1. Introduction
4.2. Most active Companion Diagnostics dealmakers
4.3. Most active Companion Diagnostics partnering company profiles
Chapter 5 - Companion Diagnostics contracts dealmaking directory
5.1. Introduction
5.2. Companion Diagnostics contracts dealmaking directory
Chapter 6 - Companion Diagnostics dealmaking by technology type
Chapter 7 - Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking
Companies Mentioned
- Max Planck Institute for Infection Biology
- Nicholas Conor Institute for Pediatric Cancer Research
- Astellas Pharma
- Astellas Pharma US
- Translational Drug Development
- IncellDx
- Seattle Genetics
- The Fleury Group
- Singulex
- WAVE Life Sciences
- RedHill Biopharma
- Cornell University
- HistologiX
- Cephalon
- Q2 Solutions
- Inform Genomics
- Inserm Transfert
- Merrimack Pharmaceuticals
- USBiomarkers
- CombiMatrix
- Epizyme
- Genzyme
- Exosome Diagnostics
- OrigiMed
- Q BioMed
- Informed Data Systems
- NeuroMetrix
- Pure MHC
- Epitomics
- IMIDomics
- Astrimmune
- Multimmune
- Biogen
- Qiagen
- QIAGEN (Suzhou) Translational Medicine Center
- Fusion Antibodies
- Aushon BioSystems
- Shuwen Biotech
- German Cancer Research Center
- Becton Dickinson
- German Federal Ministry of Education and Research
- London Genetics
- Golden Helix
- Gibson Oncology
- Dalton Pharma Services
For more information about this report visit https://www.researchandmarkets.com/r/wegm0f
